TScan Therapeutics Announces Presentation at the 11th Annual SVB Leerink Global Healthcare Conference

Rhea-AI Summary

TScan Therapeutics (Nasdaq: TCRX) will present at the 11th Annual SVB Leerink Global Healthcare Conference on February 18, 2022, at 12:00 p.m. ET. The presentation will focus on the company’s T-cell receptor (TCR) engineered therapies for cancer treatment, including lead candidates TSC-100 and TSC-101, targeting hematologic malignancies. A webcast of the event will be accessible via the company’s website and will remain available for 60 days post-event.

Positive

• Company's TCR-T therapies aim to eliminate residual leukemia and prevent relapse.
• Development of multiplexed TCR-T therapies for various solid tumors.
• Possession of an extensive ImmunoBank collection of solid tumor targets.

Negative

• None.

WALTHAM, Mass., Feb. 10, 2022 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced that the Company will present virtually at the 11^th Annual SVB Leerink Global Healthcare Conference on Friday, February 18, 2022, at 12:00 p.m. Eastern Time.

A webcast of the presentation will be available on the “Events and Presentations” section of the Company’s website at ir.tscan.com. An archived replay of the webcast will be available on the Company’s website for 60 days following the event.

About TScan Therapeutics, Inc.

TScan is a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The Company’s lead liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. The Company is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors. The Company has developed and continues to build its ImmunoBank, one of the most extensive collections of known and novel solid tumor targets across different HLA types in the TCR field.

Contact

TScan Therapeutics, Inc.
Heather Savelle
VP, Investor Relations
857-399-9840
hsavelle@tscan.com

FAQ

When will TScan Therapeutics present at the SVB Leerink Global Healthcare Conference?

TScan Therapeutics will present on February 18, 2022, at 12:00 p.m. Eastern Time.

What are the lead candidates of TScan Therapeutics?

The lead candidates are TSC-100 and TSC-101, targeting hematologic malignancies.

Where can I watch the presentation by TScan Therapeutics?

The presentation can be watched via a webcast on TScan's website.

How long will the webcast of TScan Therapeutics' presentation be available?

The archived replay of the webcast will be available for 60 days following the event.

What is the focus of TScan Therapeutics' therapies?

The therapies focus on developing T-cell receptor engineered therapies for cancer treatment.